Skip to main content
Implanet SA logo

Implanet SA — Investor Relations & Filings

Ticker · ALIMP ISIN · FR0013470168 LEI · 969500CIMHFWNM4J4V14 PA Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2021-07-06 Earnings Release
Country FR France
Listing PA ALIMP

About Implanet SA

http://www.implanet.com/en

Implanet is a medical technology company that designs, manufactures, and markets a range of implants and instruments for orthopedic surgery, with a specialized focus on spinal applications. The company's core offering is centered around its flagship Jazz™ platform, a latest-generation hybrid posterior fixation system intended to improve the treatment of various spinal disorders, including scoliosis. The product portfolio also includes other spinal systems such as Zeus™ and Saxxo™, Swingo™ interbody cages, Origin™ anterior cervical plates, and the Olea™ system for ultrasonic osteotomy. Additionally, Implanet provides complementary solutions like Neobone™ bone grafts. The company's products are utilized by surgeons and healthcare professionals in the field of spinal surgery.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 98% confidence The document is titled "IMPLANET annonce un chiffre d'affaires consolidé de 2,04 M€ au T2 2021" and contains detailed financial figures (Chiffre d'affaires) for the second quarter (T2 2021) and the first half (S1 2021) of the year, comparing them to previous periods (2020, 2019). This content structure—announcing key financial metrics for a specific recent period—is characteristic of an Earnings Release (ER). It provides the highlights and key figures immediately, rather than being a comprehensive, audited annual report (10-K) or a detailed management discussion (MDA). It is not a transcript (CT) or a formal proxy/governance document. The document also mentions the next event: "Résultats du 1er semestre 2021, le 21 septembre 2021 après bourse," which confirms this is an announcement related to periodic results. Q2 2021
2021-07-06 French
Inside Information / Other news releases
Earnings Release Classification · 98% confidence The document is titled "IMPLANET announces consolidated revenue of €2.04 million for Q2 2021" and provides detailed financial figures for the second quarter and first half of 2021, comparing them to previous years (2020 and 2019). It includes a CEO quote, a financial table, and an outlook section. This content structure is characteristic of an initial announcement of periodic financial results, focusing on key figures rather than the comprehensive detail found in a full Quarterly Report (IR) or Annual Report (10-K). The document explicitly states the period covered (Q2 2021) and provides the highlights immediately. Therefore, it fits the definition of an Earnings Release (ER). Q2 2021
2021-07-06 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic distribution partnership between IMPLANET and ulrich medical® for spinal implants. It details the scope of the agreement, quotes management, and crucially, lists upcoming financial events ('H1 2021 revenue', 'H1 2021 results'). This structure—a business update announcement with forward-looking financial event dates, rather than a full financial report (like 10-K or IR) or a transcript—is characteristic of a general corporate announcement. Since it is not a specific filing like a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), and it is not a report itself, the most appropriate general category for a significant business development announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for official company news releases.
2021-06-22 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated June 22, 2021, announcing a strategic distribution partnership between IMPLANET and ulrich medical® for spinal implants in Germany and other European countries. It details the agreement, quotes management, and lists upcoming financial events (H1 2021 revenue and results). This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA), but rather a general corporate update about business development, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a 'Capital/Financing Update' (CAP) if the partnership involved significant financial terms, but the primary focus here is on distribution and market expansion, making RNS the most appropriate general category for non-standard announcements, or potentially a Legal/Transaction related filing if it were a merger, which it is not. Given the options, and since it is a press release announcing a business development rather than a specific financial report or insider transaction, RNS (Regulatory Filings/General Announcement) is the most suitable fallback, although it shares characteristics with an M&A announcement (TAR) if the partnership was highly strategic, but it is explicitly a distribution contract, not a merger or takeover. Since there is no specific category for 'Business Development Press Release', RNS is the best fit for a general, non-standard corporate announcement.
2021-06-22 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 15, 2021, announcing a new exclusive distribution agreement between IMPLANET and GLOBUS MEDICAL for a specific medical device in France. It details the strategic importance of this partnership and includes forward-looking statements about upcoming financial events (H1 2021 revenue and results). This type of announcement, which details a significant business development (partnership/contract) but is not a formal regulatory financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or news releases. Since it is a specific business update that doesn't fit the defined categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), the most appropriate general category for a significant, non-standard corporate announcement is Regulatory Filings (RNS), which serves as a broad category for official company news releases that aren't covered elsewhere. The document length (4234 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2021-06-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 94% confidence The document is a press release dated June 15, 2021, announcing an exclusive distribution contract between IMPLANET and GLOBUS MEDICAL for a specific medical device in France. It details a business development/partnership, mentions upcoming financial events (H1 2021 revenue and results), and provides company background. This type of announcement, which is a material business update but not a formal regulatory filing like a 10-K, ER, or IR, typically falls under general regulatory announcements or news releases. Since it is a specific business development announcement and not a standard financial report, it does not fit perfectly into the defined financial report codes (10-K, IR, ER). It is a significant, non-financial-specific corporate action announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, material corporate news release that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). The document length (3991 chars) is short enough that it is not a comprehensive report itself.
2021-06-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.